Understand the source comparison
Skin Pigmentation Peptides 2026 Update: Comparison
| Peptide Class | Primary Mechanism | Molecular Weight | Documented Dermal Penetration | Clinical Efficacy (MASI Reduction) | Stability pH Range | Typical Adverse Events ||—|—|—|—|—|—|| α-MSH Receptor Antagonists (ASIP analogs) | Block MC1R signaling, prevent
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide Class | Primary Mechanism | Molecular Weight | Documented Dermal Penetration | Clinical Efficacy (MASI Reduction) | Stability pH Range | Typical Adverse Events ||—|—|—|—|—|—|| α-MSH Receptor Antagonists (ASIP analogs) | Block MC1R signaling, prevent tyrosinase upregulation | 1,200–1,800 Da | Yes (liposomal delivery required) | 40–60% at 12–16 weeks | pH 4.0–7.0 | Mild erythema (<8%) || Tyrosinase-Inhibiting Tripeptides (GHK, oligopeptide-34) | Chelate copper in tyrosinase active site | 300–500 Da | Limited (passive diffusion only if <500 Da) | 25–35% at 12 weeks | pH 5.5–7.0 (loses activity below 5.5) | Contact dermatitis (5–10%) || Oligopeptide-68 (Biomimetic Melanostatin) | Inhibits melanosome transfer to keratinocytes | 800–1,000 Da | Yes (liposomal or CPP-conjugated) | 35–50% at 10–14 weeks | pH 5.0–6.5 | Transient dryness (12–15%) || Hexapeptide-2 (Synthetic Agouti Analog) | Competitively inhibits α-MSH binding to MC1R | 680 Da | Moderate (requires penetration enhancer o